Enquiry Now
Loading...
| A02320 | Pages: NA | Aug 2021 | 6877 Views | | |
| Author(s) : NA | Tables: NA | Charts: NA |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Pregabalin Market
Request Now !Pregabalin is an anticonvulsant drug used for the treatment of epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder. Its mode of action involves decrease in pain signals sent by the damaged nerves in the body.
Increase in geriatric population suffering from neuropathic diabetes and rise in prevalence of diabetes, HIV, cancer, epilepsy, fibromyalgia, and other such disorders are expected to drive the Pregabalin market. According to the Global Year Against Neuropathic Pain 2014-2015 report by International Association of the Study of Pain, around 7%8% of adults suffer from chronic pain with neuropathic characteristics. Furthermore, Pfizers patent expiry of Lyrica (Pregabalin) in 2018 is anticipated to increase the market share of generic manufacturing companies in the UK.
However, stringent government regulations, lack of awareness about neuropathic pain, presence of substitutes of Pregabalin such as gabapentin, and adverse drug effects hinder the market growth. High investment in developing nations are proving new opportunities for the market players.
The Pregabalin market is segmented on the basis of application, end user, and geography. Based on application, the market is divided into epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder. Based on the end user, it is classified into research institutes, pharmaceutical companies, and others (hospitals and clinics). Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Benefits
List of players profiled in the report
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities
CHAPTER 4 PREGABALIN MARKET, BY APPLICATION
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. EPILEPSY
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. NEUROPATHIC PAIN
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4. FIBROMYALGIA
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
4.5. GENERALIZED ANXIETY DISORDER
4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast
CHAPTER 5 PREGABALIN MARKET, BY END USER
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. RESEARCH INSTITUTES
5.2.1. Market size and forecast
5.3. PHARMACEUTICAL COMPANIES
5.3.1. Market size and forecast
5.4. OTHERS
5.4.1. Market size and forecast
CHAPTER 6 PREGABALIN MARKET, BY GEOGRAPHY
6.1. OVERVIEW
6.2. NORTH AMERICA
6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast
6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast
6.2.4. North America Pregabalin Market by Application
6.2.5. North America Pregabalin Market by End-User
6.3. EUROPE
6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast
6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. Rest of Europe market size and forecast
6.3.4. Europe Pregabalin Market by Application
6.3.5. Europe Pregabalin Market by End-User
6.4. ASIA-PACIFIC
6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast
6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. India market size and forecast
6.4.3.4. Rest of Asia-Pacific market size and forecast
6.4.4. Asia-Pacific Pregabalin Market by Application
6.4.5. Asia-Pacific Pregabalin Market by End-User
6.5. LAMEA
6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast
6.5.3.1. Latin America market size and forecast
6.5.3.2. Middle East market size and forecast
6.5.3.3. Africa market size and forecast
6.5.4. LAMEA Pregabalin Market by Application
6.5.5. LAMEA Pregabalin Market by End-User
CHAPTER 7 COMPANY PROFILES
7.1. PFIZER INC.
7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments
7.2. TORRENT PHARMACEUTICALS LTD
7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments
7.3. LUPIN LIMITED
7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments
7.4. ZYDUS CADILA HEALTHCARE LTD
7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments
7.5. CIPLA LIMITED
7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments
7.6. GENESIS REMEDIES
7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments
7.7. SANOFI
7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments
7.8. MEDLEY PHARMACEUTICALS LIMITED
7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments
7.9. GENESIS BIOTEC INC
7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments
7.10. BIOMAX
7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
10%
Discount
10%
Discount
10%
Discount
10%
Discount
Enterprise
License/PDF
10%
Discount
Start reading.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
